Related Experiment Videos
Long-term follow-up after intracoronary streptokinase for myocardial infarction: a randomized, controlled study
Insights
Intracoronary streptokinase (SK) improved long-term outcomes for acute myocardial infarction (MI) patients, reducing major events and heart failure symptoms compared to standard therapy.
Area of Science:
- Cardiology
- Interventional Cardiology
Background:
- Intracoronary streptokinase (SK) shows promise for acute myocardial infarction (MI) in-hospital care.
- Long-term outcomes after SK treatment for MI remain largely unknown.
- Early intervention is crucial for acute MI patients.
Purpose of the Study:
- To evaluate the long-term outpatient course of acute myocardial infarction (MI) patients treated with intracoronary streptokinase (SK) versus standard therapy.
- To assess differences in mortality, nonfatal MIs, and symptom burden between the two treatment groups.
Main Methods:
- A randomized trial involving 50 acute MI patients presenting within 2.7 hours of symptom onset.
- Patients received either intracoronary streptokinase (n=24) or standard therapy (n=26).
- Survivors were followed for a mean of 18.7 months, with data current for 96% of patients.
Main Results:
- Coronary reperfusion occurred in 79% of SK-treated patients.
- Fewer major adverse events (death or nonfatal MI) were observed in the SK group (5) compared to the control group (10).
- Significantly lower rates of angina (p<0.01), heart failure symptoms (p<0.01), and late arrhythmias (p<0.05) were noted in the SK group.
Conclusions:
- Intracoronary streptokinase may offer long-term benefits for acute myocardial infarction patients, including reduced angina and heart failure.
- While not reaching statistical significance, trends favored SK treatment regarding major adverse events.
- Further research is warranted to confirm the long-term efficacy of intracoronary SK in acute MI management.
Abstract:
Intracoronary streptokinase (SK) may have beneficial effects on the in-hospital course of acute myocardial infarction (MI), but long-term outcome is unknown. We evaluated the outpatient course of 50 MI patients, randomly treated with either SK (n = 24) or standard therapy (n = 26), who presented within 2.7 +/- 0.7 hours of symptoms. Coronary reperfusion occurred in 19 (79%) SK patients. Survivors were followed for a mean of 18.7 months (range 11 to 28.5); information was current in 48 patients (96%). Both groups received antiplatelet therapy for 3 months. A total of five deaths occurred in the control group and two in the SK group, including one posthospital death in each. Nonfatal MIs totaled five in control patients and three in SK patients, including five posthospital MIs (three control, one SK). Differences in major events (death or nonfatal MI) favoring SK did not quite reach statistical significance (10 control vs 5 SK). Bypass surgery was performed in seven SK and four control patients (NS). Angina occurred in more control (15) than SK (six) patients (p less than 0.01), and more control patients used long-acting nitrates (14 control, three SK; p less than 0.01). Palpitations were noted by nine control and one SK patient (p less than 0.01), and documented late arrhythmias were present in four control patients and no SK survivors (p less than 0.05). Symptoms suggestive of heart failure were present in seven control and one SK patient (p less than 0.01); two control patients were hospitalized for failure. Use of beta blockers, calcium channel blockers, and other cardiac medications did not differ.(ABSTRACT TRUNCATED AT 250 WORDS)